Stamp MEM, Halwes M, Nisbet D, Collins DJ
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
Again, for ELISA and IP-IB, a recent study compared the performances of the two assays in determining Klotho measurement
Also, these are effective when the oral supplements you are consuming are not producing any results
Vaccaro V, Devine MJ, Higgs NF, Kittler JT